CVKD
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc. (CVKD) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | C- (2.0) | D- (0.9) | D (1.5) | C+ (2.6) | C- (1.9) |
| 2026-11-04 | C+ (2.5) | C- (2.0) | D- (1.0) | D- (0.9) | C+ (2.7) | D+ (1.8) |
| 2026-10-28 | C+ (2.5) | C- (2.0) | D- (1.0) | F (0.7) | C+ (2.7) | D+ (1.8) |
| 2026-10-21 | C+ (2.5) | C- (2.0) | D- (0.9) | D- (0.7) | C+ (2.6) | D+ (1.7) |
| 2026-10-14 | C+ (2.5) | C- (2.0) | D- (0.9) | F (0.6) | C+ (2.6) | D+ (1.7) |